AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.06 -1.88%

-$1.07 today

Market cap
$1.40B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.57M

Average 0.76M

ANAB Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

AnaptysBio, Inc.NASDAQ: ANAB

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables dips below year-ago levels

Q1 FY2026 accounts receivables of $8.1M fell 64.6% year over year, behind the +44.2% change in trailing-twelve-month accounts receivables. Sequentially, it fell 80.6% from the prior quarter.

Context

  • Accounts receivables amounted to 2.9% of revenue in FY2025, down 34.2 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -64.6% toward the trailing-twelve-month pace of +44.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.1M-80.6% QoQ
Last fiscal yearDec 2025
$6.92M+120.4% YoY
LTMMar 2026
-$7.86M+44.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-64.6%——
1 year+120.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
6.92M USD
Year-over-year change
+120.4%

Accounts Receivables vs competitors

How ANAB compares with its peers on the latest reported figures

  • ANAB's LTM Mar 2026 accounts receivables of $7.86M is the 2nd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +44.2% is the 4th highest of 8, against a peer median of +38.7%.
  • Accounts receivables amounts to 3.4% of revenue for ANAB, versus a peer median of 7.7%.
ANAB Competitors Peer median
Accounts Receivables for ANAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$8.54M +12.9%-8.0%8.1%
ANABAnaptysBio, Inc.LTM Mar 2026$7.86M +44.2%—3.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.81M +5438.2%+253.5%81.4%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$2.07M +38.7%+209.4%—
CNTBConnect Biopharma Holdings LimitedFY2025$776K +198.4%+512.8%1212.5%
IMVTImmunovant, Inc.LTM Sep 2026$510K +89.6%—7.2%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$183K -87.7%——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$67K -104.1%—3.5%
ANNXAnnexon, Inc.LTM Mar 2026$0 ———
QTTBQ32 Bio Inc.LTM Mar 2026$0 ——0.0%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ANAB) $0+38.7%+231.4%7.7%

Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(57.8M)(128.72M)(163.62M)(145.23M)49.61M
Depreciation & Amortization2.09M2.34M2.38M2.4M2.42M
Deferred Income Tax00000
Stock-Based Compensation15.35M27.36M33.21M34.05M36.07M
Change in Working Capital(7.49M)6.84M(324K)(66.33M)(80.73M)
Accounts Receivables(876K)(543K)(5.43M)(33.91M)6.92M
Inventory00000
Accounts Payables(4.74M)9.7M10.94M(33.84M)(87.33M)
Other Working Capital(1.87M)(2.32M)(5.83M)1.43M(313K)
Other Non-Cash Items1.93M18.6M7.56M39.77M12.31M
Operating Cash Flow(45.92M)(73.59M)(120.8M)(135.34M)19.7M
Capital Expenditures(1.37M)(358K)(807K)(358K)(87K)
Acquisitions (Net)0394.49M000
Purchases of Investments(118.66M)(802.5M)(303.92M)(380.38M)(196.41M)
Sales of Investments158.85M408.02M449.48M476.13M424.53M
Other Investing Activities15K(394.49M)000
Investing Cash Flow38.84M(394.85M)144.75M95.4M228.03M
Debt Repayment00(11.73M)34.77M(76.8M)
Common Stock Issued2.55M11.83M2.47M100.84M14.26M
Common Stock Repurchased00(50M)(456K)(68.63M)
Dividends Paid00000
Other Financing Activities249.75M32.19M(43K)(8.1M)(1.45M)
Financing Cash Flow252.3M44.02M(59.3M)127.05M(132.61M)
Effect of Forex Changes00000
Net Change in Cash245.21M(424.42M)(35.34M)87.12M115.12M
Free Cash Flow(47.29M)(73.95M)(121.61M)(135.7M)19.61M

AnaptysBio, Inc.

NASDAQ:ANAB

Intrinsic Alpha fair value

Locked

Current Price

$47.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.